BioLineRx (BLRX) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.
- BioLineRx's Income from Continuing Operations rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61000.0, marking a year-over-year increase of 10023.86%. This contributed to the annual value of -$11.3 million for FY2024, which is 7624.62% up from last year.
- BioLineRx's Income from Continuing Operations amounted to -$1.9 million in Q3 2025, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
- In the past 5 years, BioLineRx's Income from Continuing Operations ranged from a high of $6.0 million in Q4 2024 and a low of -$14.2 million during Q4 2023
- In the last 3 years, BioLineRx's Income from Continuing Operations had a median value of -$3.8 million in 2024 and averaged -$4.9 million.
- In the last 5 years, BioLineRx's Income from Continuing Operations surged by 14190.62% in 2024 and then soared by 4503.8% in 2025.
- BioLineRx's Income from Continuing Operations (Quarter) stood at -$14.2 million in 2023, then skyrocketed by 141.91% to $6.0 million in 2024, then tumbled by 131.92% to -$1.9 million in 2025.
- Its Income from Continuing Operations was -$1.9 million in Q3 2025, compared to -$2.0 million in Q2 2025 and -$2.0 million in Q1 2025.